Prescriber's Corner
Idelalisib: The First-in-Class Phosphatidylinositol 3-Kinase Inhibitor for Relapsed CLL, SLL, and Indolent NHL
Nicholas Forcello, PharmD, BCPS, BCOP, and Nidhi Saraiya, PharmD
Hartford Hospital, Hartford, Connecticut
Authors' disclosures of potential conflicts of interest are found at the end of this article.
Nicholas Forcello, PharmD, BCPS, BCOP, Department of Pharmacy Services, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102. E-mail: nicholas.forcello@hhchealth.org
J Adv Pract Oncol 2014;5:455-459 |
DOI: 10.6004/jadpro.2014.5.6.6 |
© 2014 Harborside Press®
For access to the full length article, please
sign in.
